前沿生物：FB7013境内生产药品注册临床试验申请获得受理通知书

Core Viewpoint - The company has submitted a clinical trial application for its self-developed siRNA drug targeting the MASP-2 protein, which is a key component of the complement system, to the National Medical Products Administration [1] Group 1 - On December 22, the company submitted the clinical trial application for the drug (product code: FB7013) [1] - The National Medical Products Administration accepted the clinical trial application on December 31, 2025 [1]